Acasti Pharma Inc

For the period ended Jun 30, 2024. Filed Aug 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 9, 2024

GRCE$1.86-0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

ACASTI PARMA INC.

Condensed Consolidated Statements of Shareholders' Equity

	Class A common shares
(Expressed in thousands except share data)	Number	Amount	Additional paid-incapital	Accumulated othercomprehensive loss	Accumulated deficit	Total stockholders' equity
$ · $ · $ · $ · $
Balance, March 31, 2024	9,399,404	261,038	17,862	(6,038)	(211,119)	61,743
Issuance of common shares upon cashless exercise of pre-funded warrants	740,457	—	—	—	—	—
Net loss and total comprehensive loss for the period	—	—	—	—	(2,617)	(2,617)
Stock-based compensation	—	—	238	—	—	238
Balance at June 30, 2024	10,139,861	261,038	18,100	(6,038)	(213,736)	59,364

	Class A common shares
(Expressed in thousands except share data)	Number	Amount	Additional paid-incapital	Accumulated othercomprehensive loss	Accumulated deficit	Total stockholders' equity
$ · $ · $ · $ · $
Balance, March 31, 2023	7,435,533	258,294	13,965	(6,038)	(198,266)	67,955
Net loss and total comprehensive loss for the period	—	—	—	—	(4,023)	(4,023)
Stock-based compensation	—	—	78	—	—	78
Balance at June 30, 2023	7,435,533	258,294	14,043	(6,038)	(202,289)	64,010

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.